Under the deal, Vividion's proteomics screening platform and small-molecule library will be utilized to target novel E3 ligases, as well as a range of oncology and immunology therapeutic targets.

Roche will have the exclusive right to license resulting compounds at different stages of development. Vividion will be responsible for early drug discovery and preclinical development for selected programs, according to the firm. For some of the programs, Vividion has the right to conduct clinical development up to a proof of concept, with the option to share development costs and split U.S. profits and losses with Roche.

Vividion will receive an up-front payment of $135 million, with the potential to receive payments potentially worth billions of dollars in the future for achieving preclinical, development, and commercial milestones, as well as from royalties on sales of commercialized products.